stocktrademan
7 years ago
ECYT buy 4.75
Nasdaq stocks $1-10 with 100,000 volume
bullish divergence breakout and initial pullback
bull flag
big rally due to...
Shares of Endocyte, Inc. ECYT have soared more than 150% on Oct 2, after it acquired an exclusive worldwide license to develop and commercialize ABX GmbH’s phase III-ready prostate cancer candidate 177Lu-PSMA-617.
Also, the share price increased more than 50% in pre-market trading on Oct 3. The company made an upfront payment of $12 million to ABX.
https://finance.yahoo.com/news/endocyte-inks-deal-prostate-cancer-205808521.html
normal chart
log chart